Topic: Armata Pharmaceuticals

Dr. Deborah Birx, now representing Armata Pharmaceuticals, called for weekly PCR testing of every dairy cow in the United States to track asymptomatic bird flu spread. The hosts calculate the immense cost of such a program—potentially billions of dollars per week—and suggest it is a strategy to benefit biotech firms and testing manufacturers.

The FDA issued a warning letter to Similasan, leading to the removal of homeopathic eye drops from the U.S. market. The hosts speculate on the timing of this removal relative to reports of "pink eye" symptoms associated with bird flu. They also examine the stock performance of Armata Pharmaceuticals (ARMP), noting its significant decline since going public.